FOR RESEARCH USE ONLY
Lumo-2 TRZ

CHEMICAL PROPERTIES

CAS NUMBER2023788-19-2
MOLECULAR WEIGHT4813.46 g/mol
MOLECULAR FORMULAC₂₂₅H₃₄₈N₄₈O₆₈

PHYSICAL PROPERTIES

APPEARANCEWhite to off-white lyophilized powder in sealed borosilicate glass vial.
SEQUENCETyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

Lumo-2 TRZ

Lumo-2 TRZ is a synthetic dual GIP and GLP-1 receptor agonist peptide studied in metabolic research. It binds both glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), making it a subject of significant interest in incretin biology research.

1
Free shipping on orders over $150
2-day delivery
LOT NUMBERLMO-0626-TRZ-001
REPORT NO.RPT-20001
HPLC PURITY98.50%

7× Independently Tested

HPLC PurityIndependent lab
IdentitySequence confirmed
Net ContentExact mg verified
SterilityContamination-free
EndotoxinsLAL tested
Heavy MetalsICP-MS screened
Batch ConsistencyLot-to-lot stability
TESTED

RESEARCH USE ONLY

This compound is sold strictly for in vitro research and laboratory use. Not for human or animal consumption. Not a drug, food, or supplement. By purchasing you confirm you are a qualified researcher and will use this compound in compliance with all applicable laws. Must be 21 or older.

RESEARCH

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine · 2022
Phase III RCT demonstrating up to 20.9% mean body weight reduction with Tirzepatide 15mg vs placebo across 72 weeks in adults with obesity — the pivotal SURMOUNT-1 trial.
PMID 35658024
Dual GIP and GLP-1 Receptor Agonist Tirzepatide: A Review of Preclinical and Clinical Data
Min T, Bain SC. · Diabetes Therapy · 2021
Reviews the dual GIP/GLP-1 receptor agonism mechanism of Tirzepatide, preclinical metabolic data, and Phase I/II clinical results demonstrating superior glycaemic and weight outcomes vs GLP-1 monotherapy.
PMID 34105078

LAB RESULTS

LOT LMO-0626-TRZ-001 · CURRENT

Certificate of Analysis

PURITY
98.50%
CAS
2023788-19-2
MW
4813.46 g/mol
APPEARANCE
White to off-white lyophilized powder in sealed borosilicate glass vial.
VERIFIED

Third-Party Report

TESTING LABIndependent Analytics LLC
TEST DATEJanuary 2025
METHODS USED
HPLCMSAAA
RESEARCH APPLICATIONS

What the literature covers.

  • Dual GIPR and GLP-1R agonist — studied for simultaneous incretin receptor activation
  • Glucose-dependent insulinotropic pathway research in metabolic cell models
  • Comparative receptor binding affinity studies vs single-agonist GLP-1 analogues
  • Incretin hormone signaling cascade investigations in vitro

All compounds sold by Lumo are intended strictly for in vitro research and laboratory use only. These products are NOT intended for human consumption, medical, veterinary, or household use. By purchasing from Lumo, you acknowledge that you are a qualified researcher or institution and will use these products solely for research purposes in compliance with all applicable laws and regulations.

L-003

Stay current.

New lot releases, research updates, and product announcements.

Unsubscribe anytime. Research use communications only.

Research Use Only · Not for Human Consumption · For Laboratory Research Purposes Only

Your Cart

● All items for research use only. Not for human consumption.

Your cart is empty

Add compounds to get started